A breakthrough in HIV prevention has brought hope to millions worldwide with a groundbreaking annual injection that could offer year-long protection. Researchers have successfully passed an early safety trial, demonstrating the drug lenacapavir’s potential as a long-lasting form of prevention.
Currently, individuals at risk of HIV must take daily pills or receive injections every eight weeks as part of pre-exposure prophylaxis (PrEP). However, these regular doses can be challenging to maintain. The prospect of an annual injection could significantly improve accessibility and adherence to HIV prevention methods.
In the initial trial, 40 participants who did not have HIV received a single muscle injection of lenacapavir, showing no major side effects or safety concerns. Traces of the medication remained in their bodies after 56 weeks, suggesting its potential as an annual PrEP option.
The development has sparked excitement among HIV advocacy groups, with one organization calling it “as exciting as it is transformational.” The drug’s success could play a key role in global efforts to curb the HIV epidemic, particularly in regions where access to prevention methods is currently limited.
Source: https://interestingengineering.com/health/annual-hiv-shot-passes-safety-trial